top of page

Therapeutic Development Pipeline

Diagnostic Pipeline

AEZS Diag_pipe_1.2023.png

Sales of Macrilen® (macimorelin) are temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency ("AGHD"), until anticipated re-launch with an alternate commercialization partner. Aeterna has an ongoing effort to identify strategic development and commercialization partner.


Specialty Biopharmaceutical Company

Data delayed 15 minutes unless otherwise indicated

bottom of page